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Background: Rats subjected to bile duct ligation (BDL) exhibit increased systemic
oxidative stress and brain dysfunction characteristic of hepatic encephalopathy (HE),
including fatigue, neurotransmitter alterations, cognitive and motor impairment, and
brain inflammation. The levels of tumor necrosis factor-alpha (TNF-α) and asymmetric
dimethylarginine (ADMA) are both increased in plasma and brain in encephalopathy
induced by chronic liver failure. This study first determined the temporal profiles of TNF-α
and ADMA in the plasma, brain cortex, and hippocampus in young BDL rats. Next, we
examined whether etanercept was beneficial in preventing brain damage.
Methods: Young rats underwent sham ligation or BDL at day 17 ± 1 for 4 weeks.
Treatment group rats were administered etanercept (10 mg/kg) intraperitoneally (IP)
three times per week with or without etanercept (100 µg) intrathecally (IT) three times in
total.
Results: We found increased plasma TNF-α, soluble tumor necrosis factor receptor 1
(sTNFR1), soluble tumor necrosis factor receptor 2 (sTNFR2), and ADMA levels,
increased cortical TNF-αmRNA and protein and ADMA, and hippocampal TNF-αmRNA
and protein, and spatial defects in young BDL rats. The increase in cortex TNF-α mRNA
and ADMA were reduced by IP etanercept or combined IP and IT etanercept. Dually
IP/IT etanercept administration reduced the increased cortical and hippocampal TNF-α
mRNA and protein level as well as spatial deficits.
Conclusions: We conclude that combined intraperitoneal and intrathecal etanercept
reduce increased brain TNF-α and ADMA levels and rescues spatial deficits in young
rats after BDL.
Keywords: asymmetric dimethylarginine, bile duct ligation, etanercept, intrathecal, spatial memory, tumor
necrosis factor-α, young age
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BACKGROUND
Hepatic encephalopathy (HE) is a complex neuropsychiatric
syndrome present in patients with liver disease that
is characterized by personality changes, diminished
intellectual capacity, motor incoordination, and consciousness
disturbance (Collie, 2005; Häussinger and Sies, 2013). Bile
duct ligation (BDL) in rats can result in chronic liver
failure with accompanying brain dysfunction that are
characteristic of HE, including changes in neurotransmitters
(Celik et al., 2005; Dhanda and Sandhir, 2015), cognitive
and motor impairment (Huang et al., 2009; Magen
et al., 2010), and brain inflammation (Rodrigo et al.,
2010).
Tumor necrosis factor-alpha (TNF-α) is a central
proinflammatory cytokine, with pleiotropic effects on
inflammatory and immunological processes (McCoy and
Tansey, 2008; Clark et al., 2010). Circulating levels of TNF-α
are not only increased in patients with chronic liver failure but
also correlate significantly with the severity of HE (Odeh et al.,
2004; Jain et al., 2013). Animal studies also show increased
TNF-α levels in acute (Chastre et al., 2012; D’Mello et al., 2015)
and chronic liver failure (Balasubramaniyan et al., 2012). Odeh
proposes that TNF-α plays a central role in the pathogenesis of
HE associated with both acute and chronic liver failure (Odeh,
2007).
Asymmetric dimethylarginine (ADMA) is a naturally
occurring amino acid that can competitively inhibit nitric
oxide synthase (NOS), thereby decreasing the synthesis of NO
(Vallance et al., 1992). ADMA and NO are both involved in
cognition (Edwards and Rickard, 2007; Miralbell et al., 2013).
Bajaj et al. (2013) found that patients with liver cirrhosis
had poor cognition and higher serum ADMA. Similarly,
young BDL rats exhibit increased circulating and hepatic
ADMA levels as well as cognition deficits (Huang et al., 2010;
Sheen et al., 2014).
A previous study showed that treatment of cultured
rat fibroblast-like synoviocytes with TNF-α significantly
increased the levels of ADMA and decreased the expression
of dimethylarginine dimethyl-aminohydrolase 2 (DDAH2)
mRNA and protein (Chen et al., 2013); these effects of
TNF-α were abolished by DDAH2 overexpression (Chen
and Zhang, 2011). ADMA has been implicated in the
inflammatory response and production of TNF-α in cultured
endothelial cells (Chen et al., 2007). Moreover, anti-TNF-α
therapy may improve the plasma L-arginine/ADMA ratio
in patients with inflammatory arthropathies (Angel et al.,
2012).
Etanercept is a dimeric recombinant form of the
extracellular domain of the human p75 TNF-α receptor
2 fused to the Fc fragment of human immunoglobulin G1
(Banks et al., 1995; Wong et al., 2008). Peripheral systemic
etanercept administration can delay the progression of
azoxymethane-induced HE in C57BL/6 mice by reducing
hepatocellular damage and decreasing both systemic
and central inflammation (Chastre et al., 2012). In
addition, perispinal administration of etanercept has been
shown to be an effective therapy for brain disorders
(Tobinick, 2009, 2010). However, etanercept does not
cross the blood-brain barrier (BBB) when administered
systemically (Banks et al., 1995). Few studies have used the
intrathecal/intraventricular route to deliver an anti-TNF-α
drug for treating brain disease (Heldmann et al., 2005;
Riazi et al., 2008; Medeiros et al., 2010; Shi et al., 2011;
Camara et al., 2015). Specifically, direct administration of
anti-TNF-α medicine into the brain parenchyma or the
cerebrospinal space for the treatment of HE has never been
reported.
The aims of this study were two-fold. The first was to study
the temporal profiles of TNF-α and ADMA in the plasma,
cortex, and hippocampus of young BDL rats. The second aim
was to examine whether peripherally with or without centrally
administered etanercept was beneficial in preventing brain
damage in young BDL rats, and if so, to examine the underlying
mechanisms.
MATERIALS AND METHODS
Animals and Experimental Design
All experiments were carried out according to the Guidelines
for Animal Experiments of Chang Gung Memorial Hospital
and Chang Gung University and approved by the Institutional
Animal Care and Use Committee of the Kaohsiung Chang
Gung Memorial Hospital (reference number: 2015031903). Male
and female Sprague-Dawley rats were obtained (BioLASCO
Taiwan, Taipei, Taiwan) for breeding. The day of delivery
was defined as day 0. Male offspring rats at postnatal day
(PND) 17 ± 1 weighing approximately 50 g were used. All
animals were housed in a room maintained at 24◦C with 12-h
light/dark cycles. All animals had free access to standard chow
and water.
BDL rats were generated as we previously described (Sheen
et al., 2010). We chose two time points, 2 weeks and 4 weeks,
because 2 weeks of BDL represents the liver fibrogenesis stage
and 4 weeks of BDL represents the chronic liver cirrhosis
stage (Georgiev et al., 2008). In cohort 1, four experimental
groups were defined. Rats that underwent sham treatment
for 2 or 4 weeks at PND 17 ± 1 were designated as
the SHAM2W group (N = 10) and the SHAM4W group
(N = 10), respectively. Rats that underwent BDL for 2 or
4 weeks at PND 17 ± 1 were designated as the BDL2W
group (N = 10) and BDL4W group (N = 10), respectively
(Figure 1). In cohort 2, five experimental groups were defined.
Rats that underwent sham ligation for 4 weeks at PND 17 ± 1
were designated as the SHAM group (N = 9). Rats that
underwent sham ligation for 4 weeks at PND 17 ± 1 and
were injected with etanercept (10 mg/kg) intraperitoneally (IP)
every other day from PND 18 ± 1 to PND 38 ± 1 (12
doses in total) and etanercept (100 µg) intrathecally (IT)
from PND 30 ± 1 to PND 38 ± 1 (3 doses in total)
were designated as the SHAMPT group (N = 9). Rats that
underwent BDL for 4 weeks at PND 17 ± 1 were designated
as the BDL4W group (N = 9). Rats that underwent BDL
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FIGURE 1 | The two subject cohorts used in this study. Cohort 1 was used to compare the levels of tumor necrosis factor-α (TNF-α) and asymmetric
dimethylarginine (ADMA) in the plasma, cortex, and hippocampus between the bile duct ligation (BDL) 2 week (BDL2W) or 4 week (BDL4W) group and the SHAM
control group of rats. Cohort 2 was used to examine the changes in biochemistry, TNF-α, ADMA, and Morris water-maze performance in the BDL4W rats after
etanercept treatment. SHAM, sham ligation for 4 weeks; SHAMPT, sham ligation for 4 weeks and injected with etanercept (10 mg/kg) intraperitoneally (IP) on
postnatal day (PND) 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 (12 doses in total) and etanercept (100 µg) intrathecally (IT) on PND 31, 33, and 35 (3 doses in
total); BDL, bile duct ligation for 4 weeks; BDLP, BDL plus etanercept IP, BDLPT, BDL plus etanercept IP and IT.
for 4 weeks and were injected IP with etanercept were
designated as the BDLP group (N = 9). Since BDL in rat
is characterized by both peripheral and central inflammation
(D’Mello et al., 2009), we therefore combined IT with IP
etanercept to examine the possible effects. Rats that underwent
BDL for 4 weeks and were injected IP and IT with etanercept
were designated as the BDLPT group (N = 9; Figure 1). The
doses of etanercept were chosen empirically, based on previous
studies (Riazi et al., 2008; Chio et al., 2013; Camara et al.,
2015).
Measurement of Plasma Biochemistry
Parameters
Blood samples were collected by cardiac puncture. Plasma
was analyzed for aspartate aminotransferase (AST), alanine
aminotransferase (ALT), ammonia, direct bilirubin and total
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bilirubin according to previously described methods (Huang
et al., 2009).
Liver and Brain Tissue Collection
Since we previously showed impairment of spatial learning and
memory in young BDL rats (Huang et al., 2009), we examined
two regions that are critically involved in spatial performance
in rats: the cortex and hippocampus (Sloan et al., 2006; Spiers
and Gilbert, 2015). Rats were euthanized on PND 45 with
ketamine (50 mg/kg) and xylazine (50 mg/kg) and the cortices,
hippocampi, and liver were removed immediately.
Liver Pathology
Liver pathology was assessed on 4-µm section blocked in paraffin
wax and stained with hematoxylin and eosin stain. The extent of
liver injury was assessed on a blind basis using a histology activity
index (HAI) score proposed by Knodell et al. (1981). Briefly,
the HAI score examined liver cell necrosis and inflammation
in four categories, including periportal necrosis, intralobular




Enzyme-linked immunosorbent assay (ELISA) analyses
were performed using appropriate kits according to the
manufacturer’s instructions, as previously reported (Huang
et al., 2009). The parameters examined included plasma TNF-α,
soluble TNF receptor 1 (sTNFR1), soluble TNF receptor
2 (sTNFR2), cortex TNF-α (R&D Systems, Inc, USA), plasma
ADMA (Immunodiagnostic AG, Bensheim, Germany), and
cortex and hippocampus ADMA (Bluegene, Shanghai, China).
Western Blotting
Western blot (WB) analysis was performed on the cortex
(100–200 µg total protein), as previously described (Tain
et al., 2010a). We used 12% gels for separation of arginine
methyltransferase 1 (PRMT1), dimethylarginine dimethyl-
aminohydrolase 1 (DDAH1), DDAH2, and cationic amino
acid transporter 1 (CAT1), and we used 8% gels for separation
of endothelial nitric-oxide synthase (eNOS) and neuronal
nitric-oxide synthase (nNOS). For TNF-α, we used a rabbit
anti-TNF-α antibody (Millipore, Billerica, MA, USA, Cat#
Ab1837P; 1:1000 dilution). For PRMT1, we used a rabbit
anti-PRMT1 antibody (Millipore, Cat# 07-404; 1:2500 dilution).
For DDAH, we used a goat anti-rat DDAH1 antibody (Santa
Cruz, CA, USA, Cat# Sc26068 1:200 dilution) and a goat anti-rat
DDAH2 antibody (Santa Cruz, Cat# Sc26071, 1:200 dilution).
For CAT1, we used a rabbit anti-CAT1 antibody (Abcam,
Cambridge, MA, USA; Cat# Ab37588; 1:250 dilution). For
eNOS, we used a mouse anti-eNOS antibody (Transduction
Laboratories, San Jose, CA, USA; Cat# 3340570; 1:250 dilution).
For nNOS, we used a mouse anti-nNOS antibody (Santa Cruz,
Cat# A11; 1:250 dilution), followed by a secondary donkey
anti-goat antibody. Bands of interest were visualized using
enhanced chemiluminescence (ECL) reagents (PerkinElmer,
Waltham, MA, USA) and quantified by densitometry (Quantity
One Analysis software; Bio-Rad, Hercules, CA, USA) as the
integrated optical density after subtraction of background.
The integrated optical density was normalized to Ponceau red
staining (Ponceau S) to correct for any variations in total protein
loading. The protein abundance was represented as integrated
optical density/Ponceau S.
Quantitative Real-Time PCR Analysis
PCR analysis was performed as reported previously (Tain
et al., 2010b). In brief, RNA was extracted and reverse
transcribed. Two-step quantitative real-time PCR was conducted
using QuantiTect SYBR green PCR reagents (Qiagen, Valencia,
CA, USA) according to the manufacturer’s protocol on a
LightCycler 480 real-time PCR system (Roche Diagnostics
Ltd., Taipei, Taiwan). β-Actin was used as a reference.
The primers for TNF-α were 5′-GGCTGCCCCGACTACGT-
3′ and 5′-AGGGCAAGGGCTCTTGATG-3′. The comparative
threshold cycle (CT) method was employed for the relative
quantification of gene expression. The averaged CT was
subtracted from the corresponding averaged β-actin value for
each sample (∆CT). ∆∆CT was obtained by subtracting the
average control ∆CT value from the average experimental ∆CT.
The fold-increase was established by calculating 2−∆∆CT for
experimental vs. control samples.
Morris Water Maze: Spatial Memory
The Morris water-maze test was conducted to assess spatial
learning and memory (Sheen et al., 2010) in all five groups of
cohort 2 from PND 38 to PND 43. Briefly, at PND 38, each rat
was habituated to the training environment. On PND 39, 40,
41 and 42, the rat was trained to find the submerged platform
and this period was considered as the acquisition phase. At
PND 43, retention of memory was tested with the platform
absent.
Astrocyte Cell Culture
Rat glioma C6 cell lines provided by American Type Culture
Collection (ATCC) were grown in RPMI medium 1640
(Life Technologies) containing 4% fetal bovine serum and
8% horse serum at 37◦C in a 5% CO2 incubator. Three
groups were designated as follows: the first was control, the
second was pre-treatment with rat TNF-α (10 pg/mL; R&D
Systems) for 1 h, and the third was pre-treatment with
rat TNF-α for 1 h with etanercept (0.1 µg/ml) added for
30 min. C6 cells were seeded (1 × 106) onto glass slides
overnight and fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) at 4◦C for 15 min. The cells were
then rinsed twice with PBS and permeabilized with 1%
Triton X-100 for 7 min. Next, the cells were pretreated
with 1% bovine serum albumin (BSA) in PBS at 25◦C for
60 min, incubated with rabbit anti-ADMA polyclonal antibodies
(Millipore) at a dilution of 1:1000 for 1 h, and treated
with fluorescein isothiocyanate (FITC)-conjugated donkey anti-
rabbit IgG polyclonal antibodies at a dilution of 1:10,000 for
1 h. Finally, the cells were washed with PBS, mounted in
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FIGURE 2 | TNF-α levels between BDL2W or BDL4W and SHAM control group rats. Plasma TNF-α (A), soluble tumor necrosis factor receptor 1 (sTNFR1)
(B), soluble tumor necrosis factor receptor 2 (sTNFR2) protein levels (C), cortex TNF-α protein level (D), cortex TNF-α mRNA (E) expression, and hippocampus
TNF-α mRNA expression (F) in rats subjected to BDL for 2 weeks or 4 weeks, and the SHAM control. One-way ANOVA, followed by a Tukey HSD post hoc test was
used to assess the statistical significance of differences between the SHAM and BDL groups, ∗P < 0.05.
90% glycerol containing 4′,6-diamidino-2-phenylindole (DAPI),
and photographed under an immunofluorescent microscope
(Olympus). In addition, the concentrations of ADMA in the
whole cell lysate were examined by ELISA.
Statistical Analysis
Biochemical parameters, liver pathology, cell culture results,
WBs, PCR, ELISA, and retention in the Morris water maze
were analyzed by one-way ANOVA with Tukey HSD post
hoc test. For the Morris water maze spatial acquisition
test, the average of the sum of the six trials per day
was analyzed by ANOVA, considering group and day as
independent variables, as well as by repeated-measure ANOVA.
All analyses were performed using SPSS. Values were expressed




To characterize the temporal profile of neuroinflammation
following BDL, we compared the levels of TNF-α in the
plasma and two regions of the brain, i.e., the cortex and
hippocampus, between BDL and SHAM groups. We found
that the BDL2W group rats had higher plasma TNF-α
(26.8 ± 3.1 pg/mL vs. 11.7 ± 0.6 pg/mL, P = 0.031), sTNFR1
(294.8 ± 8.7 pg/mL vs. 156.2 ± 8.1 pg/mL, P < 0.001), and
sTNFR2 (3632.5 ± 106.4 pg/mL vs. 1338.5 ± 65.8 pg/mL,
P < 0.001) levels as well as higher cortex TNF-α mRNA
expression (4.67 ± 1.76 vs. 1.00 ± 0.24, P < 0.001) than
the SHAM controls (Figure 2), but there were no significant
differences in cortex TNF-α protein levels (0.70 ± 0.06 pg/mg
protein vs. 0.70 ± 0.04 pg/mg protein, P = 1.00) or
hippocampus TNF-α mRNA expression (0.77 ± 0.15 vs.
1.00 ± 0.15, P = 0.660). Interestingly, the BDL4W group rats
had significantly higher cortex TNF-α protein levels (1.14± 0.06
pg/mg protein vs. 0.71 ± 0.13 pg/mg protein, P = 0.030),
and hippocampus TNF-α mRNA expression (2.74 ± 0.64 vs.
1.00 ± 0.08, P = 0.002), as well as higher plasma TNF-α
(29.8 ± 5.6 pg/mL vs. 12.6 ± 0.8 pg/mL, P = 0.004), sTNFR1
(380.1 ± 25.5 pg/mL vs. 142.5 ± 4.0 pg/mL, P < 0.001), and
sTNFR2 (3468.6 ± 225.6 pg/mL vs. 1196.1 ± 51.9 pg/mL,
P < 0.001) levels and higher cortex TNF-α mRNA expression
(9.34± 2.36 vs. 1.00± 0.11, P < 0.001) than the SHAM controls
(Figure 2).
Next, we examined the temporal profile of ADMA after
BDL. We did not find significant differences in plasma
(549.0 ± 44.3 nmol/L vs. 511.8 ± 48.1 nmol/L), cortex
(58.9 ± 4.0 µg/mg protein vs. 61.9 ± 26.0 µg/mg protein)
or hippocampus ADMA levels (22.7 ± 4.6 µg/mg protein
vs. 24.7 ± 2.9 µg/mg protein; all P = 1.00) between the
BDL2W group and SHAM controls (Figure 3). However, the
BDL4W group rats had higher plasma (899.9 ± 128.6 nmol/L
vs. 564.8 ± 26.4 nmol/L, P = 0.02) and cortex ADMA
levels (221.9 ± 33.1 µg/mg protein vs. 52.2 ± 9.3 µg/mg
protein, P = 0.003), while there was no significant difference
in the hippocampus levels (25.6 ± 1.9 µg/mg protein vs.
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FIGURE 3 | ADMA levels in BDL 2W or BDW 4W and SHAM control rats. Plasma (A), cortex (B) and hippocampus (C). One-way ANOVA, followed by a Tukey
HSD post hoc test, was used to assess the statistical significance of differences between SHAM and BDL groups, ∗P < 0.05.
TABLE 1 | Clinical parameters.
SHAM SHAMPT BDL BDLP BDLPT
N = 9 N = 9 N = 9 N = 9 N = 9
AST (IU/L) 91.1 ± 4.7 99.9 ± 6.0 359.1 ± 48.5∗ 377.1 ± 50.1 396.7 ± 30.9
ALT (IU/L) 48.7 ± 1.8 45.4 ± 2.9 128.7 ± 18.8∗ 125.1 ± 13.1 140.6 ± 8.8
Direct bilirubin (mg/dL) 0.1 ± 0.0 0.1 ± 0.0 4.4 ± 0.3∗ 4.6 ± 0.2 3.5 ± 0.1#
Total bilirubin (mg/dL) 0.4 ± 0.0 0.3 ± 0.0 6.4 ± 0.5∗ 6.7 ± 0.5 4.9 ± 0.2#
Ammonia (µg/dL) 112.4 ± 10.9 96.6 ± 7.2 461.4 ± 57.4∗ 479.6 ± 63.2 468.6 ± 61.4
Body weight (g) 246.4 ± 5.3 212 ± 6.2 205.6 ± 9.7∗ 175.3 ± 8.9# 189.7 ± 3.8
Values are means ± SEM; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SHAM, sham ligation for 4 weeks; SHAMPT, SHAM and etanercept
intraperitoneally (IP) plus intrathecally (IT); BDL, bile duct ligation for 4 weeks; BDLP, BDL plus etanercept IP; BDLPT, BDL plus etanercept IP and IT, ∗P < 0.05 vs.
SHAM; #P < 0.05 vs. BDL.
27.0 ± 6.6 µg/mg protein, P = 1.00) as compared with the
SHAM controls (Figure 3). Overall, the BDL4W group rats had
higher plasma and cortex TNF-α and ADMA levels than the
SHAM controls. Therefore, in the subsequent cohort 2 study, we
used BDL4W group rats as a model for testing the response to
etanercept.
Cohort 2
Given that etanercept does not cross the BBB, we treated
BDL4W rats with etanercept IP with/without IT etanercept
administration, to test the effect of anti-TNF-α therapy.
Liver Transaminase and Pathology
BDL4W group rats had higher plasma direct and total bilirubin,
AST, ALT, and ammonia levels than the SHAM group (Table 1).
The increases in AST, ALT, and ammonia levels were not
reversed in the BDLP or BDLPT group. Rats from the BDL4W
group had higher HAI scores compared to the SHAM group
(14.33 ± 0.53 vs. 2.20 ± 0.73, P < 0.001; Figure 4). The BDLPT
group had lower HAI scores compared to the BDL4W group
(12.00 ± 0.38 vs. 14.33 ± 0.53, P < 0.001; Figure 4). In parallel,
the BDLPT group had lower direct/total bilirubin compared to
the BDL4W group (Table 1).
Plasma and Brain TNF-α and ADMA
Cortex TNF-α protein levels were increased in the BDL4W group
compared to SHAM controls (P = 0.037) and this increase was
reduced in the BDLPT group only (P = 0.042). TNF-α mRNA
expression in the cortex was increased in the BDL4W group
compared with SHAM controls (8.29 ± 1.35 vs. 1.00 ± 0.35,
P < 0.001), and this increase was reduced in both the BDLP
and BDLPT groups (cortex BDL4W vs. BDLP 8.29 ± 1.35 vs.
1.70 ± 0.59, P < 0.001; BDL4W vs. BDLPT 8.29 ± 1.35 vs.
1.17 ± 0.05, P < 0.001). TNF-α mRNA expression and protein
levels in the hippocampus were both increased in the BDL4W
group compared with SHAM controls (P = 0.001; P = 0.010),
and these increases were both reduced only in the BDLPT
groups (P = 0.008; P = 0.009; Figure 4). The plasma levels of
TNF-α, sTNFR1, and sTNFR2 were increased in the BDL4W
group compared with SHAM controls (27.0 ± 4.9 pg/mL
vs. 2.5 ± 0.7 pg/mL, P < 0.001; 204.4 ± 27.1 pg/mL vs.
100.1 ± 4.9 pg/mL, P = 0.012; 2835.8 ± 25.3 pg/mL vs.
1574.1 ± 45.3 pg/mL, P < 0.001); however, these were not
reduced in either the BDLP or BDLPT group (Figure 5).
The level of ADMA in the cortex was increased in the BDL4W
group compared with SHAM controls (251.9 ± 54.4 µg/mg
protein vs. 61.0 ± 13.2 µg/mg protein, P = 0.001) and this
increase was reduced in both the BDLP and BDLPT groups
(251.9 ± 54.4 µg/mg protein vs. 65.8 ± 15.6 µg/mg protein,
P = 0.001; 251.9 ± 54.4 vs. 104.5 ± 29.2, P = 0.009).
The plasma level of ADMA was increased in the BDL4W
group compared with SHAM controls (1067.3 ± 67.7 nmol/L
vs. 797.7 ± 38.4 nmol/L, P = 0.014), yet this increase
was not reduced in either the BDLP or BDLPT group
(1067.3 ± 67.7 nmol/L vs. 1016.8 ± 46.1 nmol/L, P = 0.971;
1067.3 ± 67.7 nmol/L vs. 954.1 ± 117.1 nmol/L, P = 0.716;
Figure 6). These data showed that etanercept treatment
could reduce cortex and/or hippocampus TNF-α and ADMA
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FIGURE 4 | Liver injury assessed by hematoxylin and eosin staining using a histology activity index (HAI) score. One-way ANOVA, followed by a Tukey
HSD post hoc test, was used to assess the statistical significance of differences among groups, ∗P < 0.05 vs. SHAM; #P < 0.05 vs. BDL4W.
levels but had no marked effect on plasma TNF-α or
ADMA in BDL rats. Table 2 is a summary of TNF-α and
ADMA changes following peripheral and/or central etanercept
administration.
In order to investigate whether the normalization of cortex
TNF-α and ADMA in BDL rats after etanercept treatment was
related to the metabolism of ADMA, we examined the cortex
expression of DDAH1, DDAH2, PRMT1, CAT1, eNOS, and
nNOS. The level of DDAH1 was decreased in the cortex in the
BDL4W group compared with SHAM controls and this decrease
of DDAH1 was rescued in the BDLPT group only (Figure 7). No
significant differences were found in the cortex levels of DDAH2,
PRMT1, CAT1, eNOS, or nNOS between SHAM and BDL4W
groups (Figure 7).
Morris Water Maze: Spatial Memory
Given that etanercept treatment normalized cortex and/or
hippocampus TNF-α and ADMA in BDL rats, we then
investigated whether this treatment could mitigate spatial
impairment in HE rats. Figure 8 showed the mean latencies of
escape to the hidden platform as a function of days.
Acquisition: the water maze tests revealed that all rats were
able to learn how to find the platform and that there was no
significant difference in swim velocity between the different
treatment groups at any time (P > 0.1). Two-factor ANOVA
revealed significant differences among the groups for the number
of trial blocks needed to learn to escape by swimming with visual
cues (F(4,30) = 3.31, P = 0.023). Escape latencies improved over
time in all five groups as indicated by a significant effect of day
(F(3,120) = 24.24, P < 0.001), indicating that learning occurred
(Figure 8). An interaction between group and days required to
learn the task was also present (days: treatment groups, F = 3.99,
P < 0.05).
There were group differences on day 1 (F(4,30) = 3.73,
P = 0.014) and 4 (F(4,30) = 3.61, P = 0.016) of acquisition. A
post hoc test showed that BDLPT rats performed significantly
better than BDL4W and BDLP rats on day 1 (P < 0.05) and as
well as SHAM and SHAMPT rats (P > 0.05). On day 4, BDLPT
rats performed significantly better than BDL4W and BDLP rats
(P < 0.05) and as well as SHAM and SHAMPT rats (P > 0.05).
Dually IP/IT etanercept administration ameliorated the spatial
deficit, as rats in this group demonstrated a similar performance
to SHAM group rats and had faster acquisition as compared with
BDL4W group rats (P = 0.004). However, IP etanercept had no
significant effect on the spatial deficit.
Retention: the ‘‘free swim’’ trial performed immediately
after the last trial on day 5 revealed no significantly retention
differences among the five groups (F(4,31) = 0.601; P = 0.665).
Astrocyte Cell Culture and
Immunofluorescence
To determine whether etanercept can decrease the TNF-α
induced ADMA production, we treated the astrocyte cell
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FIGURE 5 | Changes in TNF-α after etanercept treatment. Plasma protein levels of TNF-α (A), sTNFR1 (B), sTNFR2 (C), levels of cortex TNF-α protein (D), and
mRNA (E) expression, and hippocampus TNF-α protein (F) and mRNA (G) expressions in the five groups. SHAM, sham ligation for 4 weeks; SHAMPT, SHAM and
etanercept IP plus IT; BDL, bile duct ligation for 4 weeks; BDLP, BDL plus etanercept IP, BDLPT, BDL plus etanercept IP and IT. One-way ANOVA, followed by a
Tukey HSD post hoc test, was used to assess the statistical significance of differences among groups, ∗P < 0.05 vs. SHAM; #P < 0.05 vs. BDL4W.
line C6 with TNF-α and applied etanercept for 30 min.
We found that immunofluorescence staining intensity of
ADMA was increased after TNF-α exposure and decreased
after etanercept application. In addition, the concentration
of ADMA in the whole cell lysate was increased following
exposure to TNF-α (22.0 ± 2.8 nmol/L vs. 13.1 ± 0.8 nmol/L,
P = 0.014) and etanercept blocked this increase in ADMA
(14.0 ± 2.6 nmol/L vs. 22.0 ± 2.8 nmol/L, P = 0.025;
Figure 9).
DISCUSSION
The main findings of this study were as follows: (1) the
BDL4W group of young rats had higher plasma TNF-α,
sTNFR1, sTNFR2, ADMA levels, higher hippocampus
TNF-α mRNA expressions and protein levels, and cortex
ADMA, TNF-α mRNA expressions and protein levels than
SHAM controls; (2) the increased cortex TNF-α mRNA
expression and cortex ADMA concentrations in BDL4W
rats were reduced in both the BDLP and BDLPT groups,
while increased cortex TNF-α protein and hippocampus
TNF-α mRNA and protein expression in BDL4W rats were
reduced in the BDLPT group alone; and (3) the BDL4W
group of young rats exhibited spatial deficits as compared
to SHAM and SHAMPT group rats, and combined IP
and IT etanercept administration (BDLPT) rescued these
effects.
In the central nervous system, microglia and astrocytes
are believed to be the primary sources of TNF-α; TNF-α
(through activation of TNFR1) disrupts learning and
memory and regulates neuronal death. TNF-α has been
implicated in the pathogenesis of a wide number of
neurological disorders that develop both acutely, as in
traumatic brain injury and stroke, and chronically, as in
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FIGURE 6 | ADMA changes after etanercept treatment. Plasma ADMA (A) and cortex ADMA (B) in the five groups. SHAM, sham ligation for 4 weeks; SHAMPT,
SHAM and etanercept IP plus IT; BDL, bile duct ligation for 4 weeks; BDLP, BDL plus etanercept IP, BDLPT, BDL plus etanercept IP and IT. One-way ANOVA,
followed by a Tukey HSD post hoc test, was used to assess the statistical significance of differences among groups, ∗P < 0.05 vs. SHAM; #P < 0.05 vs. BDL4W.
TABLE 2 | Effects of etanercept on increased peripheral and central TNF-α and Asymmetric dimethylarginine (ADMA) in bile duct ligation (BDL) rats.
TNF-α ADMA
Group Cortex Cortex Hippocampus Hippocampus Plasma Cortex
protein mRNA protein mRNA
BDLP – ↓ – – – ↓
BDLPT ↓ ↓ ↓ ↓ – ↓
BDLP, Bile duct ligation (BDL) plus etanercept intraperitoneally (IP); BDLPT, BDL plus etanercept IP and intrathecally; –, no significant changes as compared with BDL
group; ↓, decreased significantly as compared with BDL group.
Alzheimer’s disease and Parkinson’s disease (McCoy and
Tansey, 2008; Tobinick and Gross, 2008; Tuttolomondo et al.,
2008).
Previous studies have proposed serum sTNFR levels to
be markers of TNF system activation (Spengler et al., 1996;
Naveau et al., 1998). Serum levels of TNF-α, sTNFR1, and
sTNFR2 were also reported to be higher in cirrhotic patients
than those in the controls and were correlated with the
disease severity (Shiraki et al., 2010). In addition, higher serum
sTNFR2 concentrations were also related to higher mortality
in cirrhotic patients (Grünhage et al., 2008). Here we found
higher plasma TNF-α, sTNFR1, and sTNFR2 levels in both
the BDL 2W and BDL 4W group rats than their relative
SHAM controls. Our finding suggested alterations of peripheral
TNF also contributed to the pathogenesis of BDL-induced
HE.
There are many mechanisms involved in bi-directional
liver-brain proinflammatory signaling (D’Mello et al.,
2013, 2015; D’Mello and Swain, 2014). Several studies
have shown that TNF-α-secreting monocytes are recruited
into the brain in BDL rats and mice (Jiang et al., 2008;
D’Mello and Swain, 2014). In the Morris water-maze task,
rats subjected to BDL showed a progressive impairment
of spatial memory from 7 to 28 days after the BDL
procedure (Dhanda and Sandhir, 2015). In this study, we
found that there were higher plasma TNF-α levels in the
BDW 2W and BDW 4W group rats than their relative
SHAM controls. However, cortical TNF-α protein was
increased only in the BDL4W group rat. These findings
suggested that there was a discrepancy between brain and
peripheral systems in terms of temporal progression of
TNF-α.
Systemic administration of anti-TNF-α therapy attenuates
increased brain levels of TNF-α in brain disorders (Chio
et al., 2013; Detrait et al., 2014). Other studies also showed
improved brain functional outcomes after systemically
administered anti-TNF-α therapy (Chio et al., 2013;
Detrait et al., 2014; Jiang et al., 2008; Clausen et al., 2014).
Deletion of TNF receptor genes delays the onset of HE
and attenuates brain edema in azoxymethane-induced
acute liver failure (Bémeur et al., 2010). The present study
demonstrated that IP etanercept administration lowered
the increased TNF-α mRNA expression in the cortex,
while dually IP/IT etanercept administration lowered
increased cortex and hippocampus TNF-α mRNA and
protein expressions, which was accompanied by improved
spatial learning. Our data suggests that increased cortex and
hippocampus TNF-α levels may play a role in spatial deficits in
BDL-induced HE.
Both young and adult BDL rats have spatial memory deficits
(Sheen et al., 2010; Javadi-Paydar et al., 2013). Although the
correspondence between developmental stages across the two
species is not exact, PND 17 in rats can be considered as
corresponding to early childhood in humans (Clancy et al.,
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FIGURE 7 | Changes in expression of molecules related to ADMA metabolism after etanercept treatment. DDAH1, Dimethylarginine
dimethyl-aminohydrolase 1; DDAH2, dimethylarginine dimethyl-aminohydrolase 2; PRMT 1, protein arginine methyltransferase 1; CAT 1, cationic amino acid
transporter ; eNOS, endothelial nitric-oxide synthase, nNOS, neuronal nitric-oxide synthase; SHAM, sham ligation for 4 weeks; SHAMPT, SHAM and etanercept IP
plus IT; BDL, bile duct ligation for 4 weeks; BDLP, BDL plus etanercept IP, BDLPT, BDL plus etanercept IP and IT. One-way ANOVA followed by Tukey HSD post hoc
test was used to assess the statistically significances among groups, ∗P < 0.05 vs. SHAM; #P < 0.05 vs. BDL4W; $P < 0.05 vs. BDLP.
2001; Avishai-Eliner et al., 2002). The timing of insults in
the developing CNS is pivotal to the outcome, because the
development and maturation of synapses (Anderson et al.,
2011), cytokine, chemokine (Schoderboeck et al., 2009), and
neurotransmitter expression (Herlenius and Lagercrantz, 2001),
BBB maturation (Ballabh et al., 2004), redox milieus (Miller
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FIGURE 8 | Latencies of escape to the platform in the Morris water
maze (mean ± SEM). Rats in the BDL4W group swam for a longer time
while seeking to find the submerged platform on days 1 and 4 of acquisition
than did the SHAM group rats. Combined intraperitoneal and intrathecal
etanercept shortened the swim latency to a level comparable to the SHAM
group on all 4 days of acquisition. However, etanercept IP had no significant
effect on swim latency. Two-way ANOVA with repeated measures was used to
assess the statistical significance of differences among groups, ∗P < 0.05 vs.
SHAM; #P < 0.05 vs. BDL4W.
et al., 2012), and oscillation networks (Tau and Peterson, 2010)
vary widely during development. All of these parameters are
already known to be important pathogenetic factors in HE
(Celik et al., 2005; Häussinger and Schliess, 2008; Rodrigo et al.,
2010; Dhanda and Sandhir, 2015). Therefore, it is important to
study young animals with HE for both experimental and clinical
reasons.
Few studies have used the intrathecal/intraventricular
route to deliver anti-TNF-α drugs to treat brain disease
(Heldmann et al., 2005; Riazi et al., 2008; Medeiros et al.,
2010; Shi et al., 2011; Camara et al., 2015). Intraventricular
etanercept administration prevents both synaptic loss and
disruption of memory consolidation in a mouse model
of Alzheimer’s disease (Medeiros et al., 2010). Direct
intrathecal/intraventricular administration of substances is
markedly more effective for inducing behavioral changes than
the peripheral route (Adam et al., 2006; Veening and Barendregt,
2010). BDL in rats is characterized by both peripheral and
central inflammation (D’Mello et al., 2009). In this study,
we found that the dual IP/IT administration of etanercept
was effective to rescue spatial deficits in young rats with
BDL. The beneficial effects of IT administration can be due
to some physicochemical factors. The cerebrospinal fluid
may act as a broadcasting system for coordinated delivery
of messages to a variety of nearby and distant brain areas.
Some form of volume transmission may also underlie the
changes in the outcome. However, we could not exclude the
possibility that IT etanercept alone is effective in reducing
peripheral and central inflammation in BDL rats found
in this study. In clinical practice, severe liver disease may
complicate with hepatopulmonary syndrome, hepatorenal
FIGURE 9 | Staining of ADMA in intact cells and visualization by
fluorescence microscopy. (A) Representative images acquired from
cultures of rat astrocyte C6 cell lines. ADMA staining is shown in the upper
panel. DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI; middle
panels). Merged images are shown in the lower panels. (B) The concentration
of ADMA in whole cell lysates. One-way ANOVA followed by Tukey HSD post
hoc test was used to assess the statistically significances among groups,
∗P < 0.05 vs. control; #P < 0.05 vs. TNF-α incubated only.
syndrome, HE etc., and the treatment include correction
of the underlying disease and management of the various
complications (Møller and Bendtsen, 2015). While in the
brain, the therapy of HE is aimed at the treatment and
prevention of the disease-precipitating factors, including
infections, electrolyte disturbances, bleeding, and elevated
ammonia levels (Häussinger and Sies, 2013). BDL in rats is
characterized by both peripheral and central inflammation.
Peripheral monocytes are recruited into the brain and initiated
microglia activation and neuroinflammation (D’Mello and
Swain, 2014). Considering the low benefit to risk ratio,
this pre-clinical study did not investigate the effects of
IT-administered etanercept alone in BDL rats. The role of
IT-administered etanercept alone and its contribution to
the combined therapy in BDL rats with HE require further
investigation.
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 June 2016 | Volume 10 | Article 167
Sheen et al. TNF and ADMA in Hepatic Encephalopathy
The glutamate-NO-cyclic guanosine monophosphate
(cGMP) pathway is impaired in the brain of chronic moderate
hyperammonemia and HE (Corbalán et al., 2002). NO,
which is inhibited by ADMA, is critically involved in
spatial memory function (de la Torre and Aliev, 2005).
Balasubramaniyan et al. (2012) demonstrated that brain
ADMA levels were significantly higher in adult rats 4
weeks after BDL and these ADMA levels were reduced after
treatment with ornithine phenylacetate. They also showed
a concomitant increase in brain TNF-α level. Likewise,
Bajaj et al. (2013) found that patients with liver cirrhosis
had poor cognition and higher serum ADMA levels. Both
TNF-α and ADMA were increased in plasma and the brain
in encephalopathy induced by acute (Milewski et al., 2015)
or chronic liver failure (Balasubramaniyan et al., 2012). In
this study, we treated the astrocyte cell line C6 with TNF-α
and found that ADMA was increased in whole cell lysates
following exposure to TNF-α and etanercept blocked this
increase in ADMA. We also demonstrated that young rats
with BDL for 4 weeks had increased cortex ADMA levels
and that the cortical DDAH1 levels were downregulated
in BDL rats and upregulated after dual IP/IT etanercept
treatment.
In this study, dually IP/IT etanercept injections reduced
the TNF-α mRNA and protein levels in both the cortex
and the hippocampus. However, IP-administered etanercept
reversed the BDL-induced increases only in the cortical
TNF-α mRNA and ADMA protein levels. It affected neither
the cortical TNF-α protein expression nor the hippocampal
TNF-α mRNA and protein levels. The discordant response
of TNF-α mRNA and protein expression to the treatment
may be related to differences in mRNA export, ribosome
recruitment to mRNA affecting translation efficiency,
protein stability, or microRNAs (Carpenter et al., 2014;
Vélez-Bermúdez and Schmidt, 2014). Combined with
our water maze testing data, these results suggest that
changes in cortical and hippocampal TNF-α expression
might play a major role in rescuing the spatial deficit in
young BDL rats. Cortical ADMA expression appears to
play only a minor role in this process. However, the role
of increased ADMA expression in cognition needs further
investigation.
It is intriguing that the levels of both ADMA and TNF-α
were more readily decreased in the brain than the plasma
by peripheral or central etanercept administration. There are
several possibilities. First, we measured plasma TNF-α by
ELISA and cortex TNF-α by WB through recognizing the
epitope in the cohort 2 study. TNF bound to etanercept
can still be present and detectable but be unable to mediate
biological or inflammatory effects (Bhatia and Kast, 2007).
Different detection tools that recognize dissimilar epitope
may result in the inconsistent responses between plasma
and brain. Next, the liver and brain was interacted in
inflammatory liver disease. In the context of BDL, the
production of peripheral inflammatory signals may affect
the brain through humoral or neural routes as well as
through active recruitment of monocytes into the brain
(D’Mello et al., 2009; Butterworth, 2013; D’Mello and Swain,
2014). The afferent and efferent components of the vagus
nerve play a role in controlling both systemic and central
inflammation. Vagal afferents can directly sense cytokine
levels in the blood via specific cytokine receptors that are
present on the endings of these nerves in the paraganglia
located in the gastrointestinal tract, spleen, bone marrow,
liver, and heart. These nerves transmit the signals to other
brain regions to modulate inflammation (Goehler et al.,
2000; Tracey, 2002). Vagal nerve may sense the systemic
inflammation and reflex release of acetylcholine in organs to
reduce systemic inflammation by reducing proinflammatory
cytokines (Borovikova et al., 2000). Therefore, IP-administered
etanercept did not reduce the TNF-α and ADMA levels in the
plasma significantly, yet it might affect the routes connected
with the brain and decrease brain inflammation to a significant
extent. On the other hand, central signaling may also convey
the information to the liver through the sympathetic and
parasympathetic branches of the vagus nerve (Montiel-Castro
et al., 2013; Rosas-Ballina et al., 2015; Tanida et al., 2015),
so that dual IT/IP may ameliorate liver histopathology and
normalize direct and total bilirubin levels. The mechanisms
of the peripheral and central production and elimination
of inflammatory molecules are very complex and varied
(D’Mello et al., 2009, 2015; Teerlink et al., 2009; Sheen et al.,
2014).
CONCLUSION
HE is a frequent and serious complication of chronic liver
failure. This study demonstrated that young BDL rats exhibited
increased circulating and brain TNF-α and ADMA levels, as
well as spatial deficits, as in adult BDL rats, indicating that
increases in and interaction between TNF-α and ADMA play an
important role in HE. Moreover, combined IP and IT etanercept
reduce spatial deficits in young BDL rats. Appropriate targeting
of TNF-α and ADMA may offer a new treatment avenue
for HE.
AUTHOR CONTRIBUTIONS
J-MS: performed the majority of the experiments and wrote this
manuscript. Y-CC: aided in experimental design and behavioral
testing. M-HH: assisted with experimental design and aided in
serum analysis. Y-LT and H-RY: assisted with planning and
interpreting behavioral testing. L-TH: designed the study, edited
and provided final approval of this manuscript. All authors read
and approved the final manuscript.
ACKNOWLEDGMENTS
The study was supported in part by grants from Chang
Gung Memorial Hospital CMRPG8D0371 and CMRPG8D0441
to L-TH, CMRPG8C0121 and CMRPG8E0311 to J-MS and
CMRPG8D0351 to Y-CC. We thank Prof Zhi-Hong Weng from
National Sun Yat-sen University Taiwan for intrathecal technical
help.
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 June 2016 | Volume 10 | Article 167
Sheen et al. TNF and ADMA in Hepatic Encephalopathy
REFERENCES
Adam, C. L., Findlay, P. A., and Miller, D. W. (2006). Blood-brain leptin
transport and appetite and reproductive neuroendocrine responses to
intracerebroventricular leptin injection in sheep: influence of photoperiod.
Endocrinology 147, 4589–4598. doi: 10.1210/en.2006-0576
Anderson, V., Spencer-Smith, M., and Wood, A. (2011). Do children really
recover better? Neurobehavioural plasticity after early brain insult. Brain 134,
2197–2221. doi: 10.1093/brain/awr103
Angel, K., Provan, S. A., Mowinckel, P., Seljeflot, I., Kvien, T. K., and Atar,
D. (2012). The L-arginine/asymmetric dimethylarginine ratio is improved
by anti-tumor necrosis factor-α therapy in inflammatory arthropathies.
Associations with aortic stiffness. Atherosclerosis 225, 160–165. doi: 10.1016/j.
atherosclerosis.2012.08.033
Avishai-Eliner, S., Brunson, K. L., Sandman, C. A., and Baram, T. Z. (2002).
Stressed-out, or in (utero)? Trends Neurosci. 25, 518–524. doi: 10.1016/s0166-
2236(02)02241-5
Bajaj, J. S., Ahluwalia, V., Wade, J. B., Sanyal, A. J., White, M. B., Noble, N. A.,
et al. (2013). Asymmetric dimethylarginine is strongly associated with cognitive
dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J. Hepatol.
58, 38–44. doi: 10.1016/j.jhep.2012.08.005
Balasubramaniyan, V., Wright, G., Sharma, V., Davies, N. A., Sharifi, Y.,
Habtesion, A., et al. (2012). Ammonia reduction with ornithine phenylacetate
restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-
ligated cirrhotic rats. Am. J. Physiol. Gastrointest. Liver Physiol. 302,
G145–G152. doi: 10.1152/ajpgi.00097.2011
Ballabh, P., Braun, A., and Nedergaard, M. (2004). The blood-brain barrier: an
overview: structure, regulation and clinical implications. Neurobiol. Dis. 16,
1–13. doi: 10.1016/j.nbd.2003.12.016
Banks, W. A., Plotkin, S. R., and Kastin, A. J. (1995). Permeability of the
blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 2,
161–165. doi: 10.1159/000096887
Bémeur, C., Qu, H., Desjardins, P., and Butterworth, R. F. (2010). IL-1 or TNF
receptor gene deletion delays onset of encephalopathy and attenuates brain
edema in experimental acute liver failure.Neurochem. Int. 56, 213–215. doi: 10.
1016/j.neuint.2009.11.010
Bhatia, A., and Kast, R. E. (2007). Tumor necrosis factor (TNF) can paradoxically
increase on etanercept treatment, occasionally contributing to TNF-mediated
disease. J. Rheumatol. 34, 447–449.
Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I.,
Watkins, L. R., et al. (2000). Vagus nerve stimulation attenuates the
systemic inflammatory response to endotoxin. Nature 405, 458–462. doi: 10.
1038/35013070
Butterworth, R. F. (2013). The liver-brain axis in liver failure: neuroinflammation
and encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 10, 522–528. doi: 10.
1038/nrgastro.2013.99
Camara, M. L., Corrigan, F., Jaehne, E. J., Jawahar, M. C., Anscomb, H., and
Baune, B. T. (2015). Effects of centrally administered etanercept on behavior,
microglia and astrocytes in mice following a peripheral immune challenge.
Neuropsychopharmacology 40, 502–512. doi: 10.1038/npp.2014.199
Carpenter, S., Ricci, E. P., Mercier, B. C., Moore, M. J., and Fitzgerald, K. A. (2014).
Post-transcriptional regulation of gene expression in innate immunity. Nat.
Rev. Immunol. 14, 361–376. doi: 10.1038/nri3682
Celik, T., Gören, M. Z., Cinar, K., Gürdal, H., Onder, F. O., Tan, A., et al. (2005).
Fatigue of cholestasis and the serotoninergic neurotransmitter system in the
rat. Hepatology 41, 731–737. doi: 10.1002/hep.20617
Chastre, A., Bélanger, M., Beauchesne, E., Nguyen, B. N., Desjardins, P., and
Butterworth, R. F. (2012). Inflammatory cascades driven by tumor necrosis
factor-alpha play a major role in the progression of acute liver failure and
its neurological complications. PLoS One 7:e49670. doi: 10.1371/journal.pone.
0049670
Chen, X. M., Xia, J., Zhou, T., Yuan, Q., Zhang, W. F., Hu, C. P., et al. (2013).
Involvement of DDAH/ADMA pathway in the pathogenesis of rheumatoid
arthritis in rats. Int. Immunopharmacol. 16, 322–331. doi: 10.1016/j.intimp.
2013.04.009
Chen, M. F., Xie, X. M., Yang, T. L., Wang, Y. J., Zhang, X. H., Luo, B. L., et al.
(2007). Role of asymmetric dimethylarginine in inflammatory reactions by
angiotensin II. J. Vasc. Res. 44, 391–402. doi: 10.1159/000103284
Chen, M., and Zhang, L. (2011). Epigenetic mechanisms in developmental
programming of adult disease. Drug Discov. Today 16, 1007–1018. doi: 10.
1016/j.drudis.2011.09.008
Chio, C. C., Chang, C. H., Wang, C. C., Cheong, C. U., Chao, C. M., Cheng, B. C.,
et al. (2013). Etanercept attenuates traumatic brain injury in rats by reducing
early microglial expression of tumor necrosis factor-α. BMC. Neurosci. 14:33.
doi: 10.1186/1471-2202-14-33
Clancy, B., Darlington, R. B., and Finlay, B. L. (2001). Translating developmental
time across mammalian species. Neuroscience 105, 7–17. doi: 10.1016/s0306-
4522(01)00171-3
Clark, I. A., Alleva, L. M., and Vissel, B. (2010). The roles of TNF in brain
dysfunction and disease. Pharmacol. Ther. 128, 519–548. doi: 10.1016/j.
pharmthera.2010.08.007
Clausen, B. H., Degn, M., Martin, N. A., Couch, Y., Karimi, L., Ormhøj, M., et al.
(2014). Systemically administered anti-TNF therapy ameliorates functional
outcomes after focal cerebral ischemia. J. Neuroinflammation 11:203. doi: 10.
1186/s12974-014-0203-6
Collie, A. (2005). Cognition in liver disease. Liver Int. 25, 1–8. doi: 10.1111/j.1478-
3231.2005.01012.x
Corbalán, R., Montoliu, C., Miñana, M. D., Del Olmo, J. A., Serra, M. A., Aparisi,
L., et al. (2002). Altered modulation of soluble guanylate cyclase by nitric
oxide in patients with liver disease. Metab. Brain Dis. 17, 295–301. doi: 10.
1023/A:1021953717331
de la Torre, J. C., and Aliev, G. (2005). Inhibition of vascular nitric oxide after
rat chronic brain hypoperfusion: spatial memory and immunocytochemical
changes. J. Cereb. Blood. Flow. Metab. 25, 663–672. doi: 10.1038/sj.jcbfm.
9600057
Detrait, E. R., Danis, B., Lamberty, Y., and Foerch, P. (2014). Peripheral
administration of an anti-TNF-α receptor fusion protein counteracts the
amyloid induced elevation of hippocampal TNF-α levels and memory deficits
in mice. Neurochem. Int. 72, 10–13. doi: 10.1016/j.neuint.2014.04.001
Dhanda, S., and Sandhir, R. (2015). Role of dopaminergic and serotonergic
neurotransmitters in behavioral alterations observed in rodentmodel of hepatic
encephalopathy. Behav. Brain Res. 286, 222–235. doi: 10.1016/j.bbr.2015.01.042
D’Mello, C., Le, T., and Swain, M. G. (2009). Cerebral microglia recruit
monocytes into the brain in response to tumor necrosis factor alpha signaling
during peripheral organ inflammation. J. Neurosci. 29, 2089–2102. doi: 10.
1523/JNEUROSCI.3567-08.2009
D’Mello, C., Riazi, K., Le, T., Stevens, K. M., Wang, A., McKay, D. M., et al. (2013).
P-selectin-mediated monocyte-cerebral endothelium adhesive interactions
link peripheral organ inflammation to sickness behaviors. J. Neurosci. 33,
14878–14888. doi: 10.1523/JNEUROSCI.1329-13.2013
D’Mello, C., Ronaghan, N., Zaheer, R., Dicay, M., Le, T., MacNaughton, W. K.,
et al. (2015). Probiotics improve inflammation-associated sickness behavior by
altering communication between the peripheral immune system and the brain.
J. Neurosci. 35, 10821–10830. doi: 10.1523/JNEUROSCI.0575-15.2015
D’Mello, C., and Swain, M. G. (2014). Liver-brain interactions in inflammatory
liver diseases: implications for fatigue and mood disorders. Brain Behav.
Immun. 35, 9–20. doi: 10.1016/j.bbi.2013.10.009
Edwards, T. M., and Rickard, N. S. (2007). New perspectives on the mechanisms
through which nitric oxide may affect learning and memory processes.
Neurosci. Biobehav. Rev. 31, 413–425. doi: 10.1016/j.neubiorev.2006.11.001
Georgiev, P., Jochum, W., Heinrich, S., Jang, J. H., Nocito, A., Dahm, F., et al.
(2008). Characterization of time-related changes after experimental bile duct
ligation. Br. J. Surg. 95, 646–656. doi: 10.1002/bjs.6050
Goehler, L. E., Gaykema, R. P., Hansen, M. K., Anderson, K., Maier, S. F., and
Watkins, L. R. (2000). Vagal immune-to-brain communication: a visceral
chemosensory pathway. Auton. Neurosci. 85, 49–59. doi: 10.1016/s1566-
0702(00)00219-8
Grünhage, F., Rezori, B., Neef, M., Lammert, F., Sauerbruch, T., Spengler, U.,
et al. (2008). Elevated soluble tumor necrosis factor receptor 75 concentrations
identify patients with liver cirrhosis at risk of death. Clin. Gastroenterol.
Hepatol. 6, 1255–1262. doi: 10.1016/j.cgh.2008.06.018
Häussinger, D., and Schliess, F. (2008). Pathogenetic mechanisms of hepatic
encephalopathy. Gut 57, 1156–1165. doi: 10.1136/gut.2007.122176
Häussinger, D., and Sies, H. (2013). Hepatic encephalopathy: clinical aspects and
pathogenetic concept. Arch. Biochem. Biophys. 536, 97–100. doi: 10.1016/j.abb.
2013.04.013
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 June 2016 | Volume 10 | Article 167
Sheen et al. TNF and ADMA in Hepatic Encephalopathy
Heldmann, U., Thored, P., Claasen, J. H., Arvidsson, A., Kokaia, Z., and Lindvall,
O. (2005). TNF-alpha antibody infusion impairs survival of stroke-generated
neuroblasts in adult rat brain. Exp. Neurol. 196, 204–208. doi: 10.1016/j.
expneurol.2005.07.024
Herlenius, E., and Lagercrantz, H. (2001). Neurotransmitters and
neuromodulators during early human development. Early Hum. Dev. 65,
21–37. doi: 10.1016/s0378-3782(01)00189-x
Huang, L. T., Chen, C. C., Sheen, J. M., Chen, Y. J., Hsieh, C. S., and Tain,
Y. L. (2010). The interaction between high ammonia diet and bile duct
ligation in developing rats: assessment by spatial memory and asymmetric
dimethylarginine. Int. J. Dev. Neurosci. 28, 169–174. doi: 10.1016/j.ijdevneu.
2009.11.006
Huang, L. T., Tiao, M. M., Tain, Y. L., Chen, C. C., and Hsieh, C. S. (2009).
Melatonin ameliorates bile duct ligation-induced systemic oxidative stress and
spatial memory deficits in developing rats. Pediatr. Res. 65, 176–180. doi: 10.
1203/PDR.0b013e31818d5bc7
Jain, L., Sharma, B. C., Srivastava, S., Puri, S. K., Sharma, P., and Sarin, S.
(2013). Serum endotoxin, inflammatory mediators and magnetic resonance
spectroscopy before and after treatment in patients with minimal hepatic
encephalopathy. J. Gastroenterol. Hepatol. 28, 1187–1193. doi: 10.1111/jgh.
12160
Javadi-Paydar, M., Ghiassy, B., Ebadian, S., Rahimi, N., Norouzi, A., and Dehpour,
A. R. (2013). Nitric oxide mediates the beneficial effect of chronic naltrexone
on cholestasis-induced memory impairment in male rats. Behav. Pharmacol.
24, 195–206. doi: 10.1097/FBP.0b013e3283618a8c
Jiang, Y., Deacon, R., Anthony, D. C., and Campbell, S. J. (2008). Inhibition
of peripheral TNF can block the malaise associated with CNS inflammatory
diseases. Neurobiol. Dis. 32, 125–132. doi: 10.1016/j.nbd.2008.06.017
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz,
N., et al. (1981). Formulation and application of a numerical scoring system
for assessing histological activity in asymptomatic chronic active hepatitis.
Hepatology 1, 431–435. doi: 10.1002/hep.1840010511
Magen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., and Berry,
E. M. (2010). Cannabidiol ameliorates cognitive and motor impairments in
bile-duct ligated mice via 5-HT1A receptor activation. Br. J. Pharmacol. 159,
950–957. doi: 10.1111/j.1476-5381.2009.00589.x
McCoy, M. K., and Tansey, M. G. (2008). TNF signaling inhibition in the
CNS: implications for normal brain function and neurodegenerative disease.
J. Neuroinflammation 5:45. doi: 10.1186/1742-2094-5-45
Medeiros, R., Figueiredo, C. P., Pandolfo, P., Duarte, F. S., Prediger, R. D., Passos,
G. F., et al. (2010). The role of TNF-alpha signaling pathway on COX-2
upregulation and cognitive decline induced by beta-amyloid peptide. Behav.
Brain Res. 209, 165–173. doi: 10.1016/j.bbr.2010.01.040
Milewski, K., Hilgier, W., Albrecht, J., and Zielin´ska, M. (2015). The
dimethylarginine (ADMA)/nitric oxide pathway in the brain and periphery of
rats with thioacetamide-induced acute liver failure: modulation by histidine.
Neurochem. Int. 88, 26–31. doi: 10.1016/j.neuint.2014.12.004
Miller, S. L., Wallace, E. M., and Walker, D. W. (2012). Antioxidant therapies:
a potential role in perinatal medicine. Neuroendocrinology 96, 13–23. doi: 10.
1159/000336378
Miralbell, J., López-Cancio, E., López-Oloriz, J., Arenillas, J. F., Barrios, M.,
Soriano-Raya, J. J., et al. (2013). Cognitive patterns in relation to biomarkers of
cerebrovascular disease and vascular risk factors. Cerebrovasc. Dis. 36, 98–105.
doi: 10.1159/000352059
Møller, S., and Bendtsen, F. (2015). Complications of cirrhosis. A 50 years
flashback. Scand. J. Gastroenterol. 50, 763–780. doi: 10.3109/00365521.2015.
1021709
Montiel-Castro, A. J., González-Cervantes, R.M., Bravo-Ruiseco, G., and Pacheco-
López, G. (2013). The microbiota-gut-brain axis: neurobehavioral correlates,
health and sociality. Front. Integr. Neurosci. 7:70. doi: 10.3389/fnint.2013.
00070
Naveau, S., Emilie, D., Balian, A., Grangeot-Keros, L., Borotto, E., Portier, A., et al.
(1998). Plasma levels of soluble tumor necrosis factor receptors p55 and p75
in patients with alcoholic liver disease of increasing severity. J. Hepatol. 28,
778–784. doi: 10.1016/s0168-8278(98)80227-4
Odeh, M. (2007). Pathogenesis of hepatic encephalopathy: the tumour necrosis
factor-alpha theory. Eur. J. Clin. Invest. 37, 291–304. doi: 10.1111/j.1365-2362.
2007.01778.x
Odeh, M., Sabo, E., Srugo, I., and Oliven, A. (2004). Serum levels of tumor necrosis
factor-alpha correlate with severity of hepatic encephalopathy due to chronic
liver failure. Liver Int. 24, 110–116. doi: 10.1111/j.1478-3231.2004.0894.x
Riazi, K., Galic, M. A., Kuzmiski, J. B., Ho, W., Sharkey, K. A., and Pittman, Q. J.
(2008). Microglial activation and TNFalpha production mediate altered CNS
excitability following peripheral inflammation. Proc. Natl. Acad. Sci. U S A 105,
17151–17156. doi: 10.1073/pnas.0806682105
Rodrigo, R., Cauli, O., Gomez-Pinedo, U., Agusti, A., Hernandez-Rabaza,
V., Garcia-Verdugo, J. M., et al. (2010). Hyperammonemia induces
neuroinflammation that contributes to cognitive impairment in rats with
hepatic encephalopathy. Gastroenterology. 139, 675–684. doi: 10.1053/j.gastro.
2010.03.040
Rosas-Ballina, M., Valdés-Ferrer, S. I., Dancho,M. E., Ochani, M., Katz, D., Cheng,
K. F., et al. (2015). Xanomeline suppresses excessive pro-inflammatory cytokine
responses through neural signal-mediated pathways and improves survival in
lethal inflammation. Brain Behav. Immun. 44, 19–27. doi: 10.1016/j.bbi.2014.
07.010
Schoderboeck, L., Adzemovic, M., Nicolussi, E. M., Crupinschi, C., Hochmeister,
S., Fischer, M. T., et al. (2009). The ‘‘window of susceptibility’’ for inflammation
in the immature central nervous system is characterized by a leaky blood-brain
barrier and the local expression of inflammatory chemokines. Neurobiol. Dis.
35, 368–375. doi: 10.1016/j.nbd.2009.05.026
Sheen, J. M., Chen, Y. C., Tain, Y. L., andHuang, L. T. (2014). Increased circulatory
asymmetric dimethylarginine and multiple organ failure: bile duct ligation in
rat as a model. Int. J. Mol. Sci. 15, 3989–4006. doi: 10.3390/ijms15033989
Sheen, J. M., Huang, L. T., Hsieh, C. S., Chen, C. C., Wang, J. Y., and Tain,
Y. L. (2010). Bile duct ligation in developing rats: temporal progression of
liver, kidney and brain damage. J. Pediatr. Surg. 45, 1650–1658. doi: 10.1016/j.
jpedsurg.2009.12.019
Shi, J. Q., Shen, W., Chen, J., Wang, B. R., Zhong, L. L., Zhu, Y. W., et al. (2011).
Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces
CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains.
Brain Res. 1368, 239–247. doi: 10.1016/j.brainres.2010.10.053
Shiraki, M., Terakura, Y., Iwasa, J., Shimizu, M., Miwa, Y., Murakami, N., et al.
(2010). Elevated serum tumor necrosis factor-alpha and soluble tumor necrosis
factor receptors correlate with aberrant energy metabolism in liver cirrhosis.
Nutrition 26, 269–275. doi: 10.1016/j.nut.2009.04.016
Sloan, H. L., Good, M., and Dunnett, S. B. (2006). Double dissociation between
hippocampal and prefrontal lesions on an operant delayed matching task and
a water maze reference memory task. Behav. Brain Res. 171, 116–126. doi: 10.
1016/j.bbr.2006.03.030
Spengler, U., Zachoval, R., Gallati, H., Jung, M. C., Hoffmann, R., Riethmüller, G.,
et al. (1996). Serum levels and in situ expression of TNF-alpha and TNF-alpha
binding proteins in inflammatory liver diseases. Cytokine. 8, 864–872. doi: 10.
1006/cyto.1996.0115
Spiers, H. J., and Gilbert, S. J. (2015). Solving the detour problem in navigation:
a model of prefrontal and hippocampal interactions. Front. Hum. Neurosci.
9:125. doi: 10.3389/fnhum.2015.00125
Tain, Y. L., Hsieh, C. S., Chen, C. C., Sheen, J. M., Lee, C. T., and Huang, L. T.
(2010a). Melatonin prevents increased asymmetric dimethylarginine in young
rats with bile duct ligation. J. Pineal Res. 48, 212–221. doi: 10.1111/j.1600-079x.
2010.00745.x
Tain, Y. L., Kao, Y. H., Hsieh, C. S., Chen, C. C., Sheen, J. M., Lin, I. C.,
et al. (2010b). Melatonin blocks oxidative stress-induced increased asymmetric
dimethylarginine. Free Radic. Biol. Med. 49, 1088–1098. doi: 10.1016/j.
freeradbiomed.2010.06.029
Tanida, M., Yamamoto, N., Morgan, D. A., Kurata, Y., Shibamoto, T., and
Rahmouni, K. (2015). Leptin receptor signaling in the hypothalamus regulates
hepatic autonomic nerve activity via phosphatidylinositol 3-kinase and AMP-
activated protein kinase. J. Neurosci. 35, 474–484. doi: 10.1523/JNEUROSCI.
1828-14.2015
Tau, G. Z., and Peterson, B. S. (2010). Normal development of brain circuits.
Neuropsychopharmacology 35, 147–168. doi: 10.1038/npp.2009.115
Teerlink, T., Luo, Z., Palm, F., and Wilcox, C. S. (2009). Cellular ADMA:
regulation and action. Pharmacol. Res. 60, 448–460. doi: 10.1016/j.phrs.2009.
08.002
Tobinick, E. (2009). Perispinal etanercept for neuroinflammatory disorders. Drug
Discov. Today 14, 168–177. doi: 10.1016/j.drudis.2008.10.005
Frontiers in Cellular Neuroscience | www.frontiersin.org 14 June 2016 | Volume 10 | Article 167
Sheen et al. TNF and ADMA in Hepatic Encephalopathy
Tobinick, E. (2010). Perispinal etanercept: a new therapeutic paradigm
in neurology. Expert Rev. Neurother. 10, 985–1002. doi: 10.1586/
ern.10.52
Tobinick, E. L., and Gross, H. (2008). Rapid cognitive improvement in verbal
fluency and aphasia following perispinal etanercept in Alzheimer’s disease.
BMC Neurol. 8:27. doi: 10.1186/1471-2377-8-27
Tracey, K. J. (2002). The inflammatory reflex. Nature 420, 853–859. doi: 10.
1038/nature01321
Tuttolomondo, A., Di Raimondo, D., di Sciacca, R., Pinto, A., and Licata, G.
(2008). Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des. 14,
3574–3589. doi: 10.2174/138161208786848739
Vallance, P., Leone, A., Calver, A., Collier, J., and Moncada, S. (1992).
Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis.
J. Cardiovasc. Pharmacol. 20, S60–S62. doi: 10.1097/00005344-199204002-
00018
Veening, J. G., and Barendregt, H. P. (2010). The regulation of brain states
by neuroactive substances distributed via the cerebrospinal fluid; a review.
Cerebrospinal Fluid Res. 7:1. doi: 10.1186/1743-8454-7-1
Vélez-Bermúdez, I. C., and Schmidt, W. (2014). The conundrum of discordant
protein and mRNA expression. Are plants special? Front. Plant Sci. 5:619.
doi: 10.3389/fpls.2014.00619
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., et al. (2008). TNFalpha
blockade in human diseases: mechanisms and future directions.Clin. Immunol.
126, 121–136. doi: 10.1016/j.clim.2007.08.013
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Sheen, Chen, Hsu, Tain, Yu and Huang. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution and reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 15 June 2016 | Volume 10 | Article 167
